Filed pursuant to Rule 424(b)(5)
File No. 333-230366
PROSPECTUS SUPPLEMENT
(To Prospectus dated March 18, 2019)
$267,545,979
![LOGO](https://capedge.com/proxy/424B5/0001193125-19-078395/g693549g99m83.jpg)
Common Stock
This prospectus supplement relates to the offer and sale by us of our common stock, par value $0.01 per share, having an aggregate gross sales price of up to $267,545,979 over a period of time and from time to time through Merrill Lynch, Pierce, Fenner & Smith Incorporated, Credit Suisse Securities (USA) LLC, Deutsche Bank Securities Inc., Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC and Wells Fargo Securities, LLC, (each individually, a “sales agent” and together, the “sales agents”), pursuant to a sales agreement (“sales agreement”) between us and the sales agents that we have filed with the Securities and Exchange Commission as an exhibit to a Current Report onForm 8-K filed on November 21, 2017. The amount of common stock covered by this prospectus supplement represents unsold shares of common stock previously registered under a prospectus supplement filed on November 21, 2017, in connection with our entry into the sales agreement, which was registered under our shelf registration onForm S-3, filed on April 15, 2016 (FileNo. 333-210788).
Sales of our common stock, if any, under this prospectus supplement and the accompanying prospectus may be made in sales deemed to be“at-the-market offerings” as defined in Rule 415 under the Securities Act of 1933, as amended (the “Securities Act”), including by sales made directly on or through the New York Stock Exchange (“NYSE”) or another market for our common stock, sales made to or through a market maker other than on an exchange or otherwise, in negotiated transactions at market prices prevailing at the time of sale or at negotiated prices, or as otherwise agreed with the applicable sales agent. We will submit orders to only one sales agent relating to the sale of shares of our common stock on any given day. Subject to the terms and conditions of the sales agreement, the sales agents will use their commercially reasonable efforts to sell on our behalf all of the designated shares. We may instruct the sales agents not to sell any shares if the sales cannot be effected at or above the price designated by us in any such instruction.
We also may sell shares of our common stock to one or more of the sales agents, as principal for their own accounts, at a price per share agreed upon at the time of sale. If we sell shares to one or more sales agents, as principal, we will enter into a separate terms agreement with such sales agent or agents, and we will describe the agreement in a separate prospectus supplement or pricing supplement.
We will pay the sales agents a commission of up to 2% of the gross sales price per share sold through them as our agent under the sales agreement. In connection with the sale of our shares of common stock on our behalf, the sales agents may be deemed to be “underwriters” within the meaning of the Securities Act, and the compensation paid to the sales agents may be deemed to be underwriting commissions or discounts.
Our common stock is listed on the NYSE under the symbol “OUT.” On March 15, 2019 the last reported sale price of our common stock on the NYSE was $22.58 per share.
To assist us in maintaining our qualification as a real estate investment trust (“REIT”) for federal income tax purposes, among other purposes, our charter contains certain restrictions on ownership and transfer of our shares of stock, including a provision restricting stockholders from owning more than 9.8%, in value or in number of shares, whichever is more restrictive, of our outstanding shares of common stock or more than 9.8% in value of the aggregate outstanding shares of all classes and series of our stock without the prior consent of our board of directors. See “Description of Common Stock—Restrictions on Ownership and Transfer” in the accompanying prospectus.
Investing in our common stock involves a high degree of risk. Before buying any common stock, you should carefully consider the risks that we have described in “Risk Factors” beginning onpage S-3 of this prospectus supplement, as well as those described in our filings under the Securities Exchange Act of 1934, as amended (the “Exchange Act”).
Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus supplement or accompanying prospectus is truthful or complete. Any representation to the contrary is a criminal offense.
| | | | | | |
BofA Merrill Lynch | | Credit Suisse | | Deutsche Bank Securities | | Goldman Sachs & Co. LLC |
| | | | |
J.P. Morgan | | Morgan Stanley | | Wells Fargo Securities |
The date of this prospectus supplement is March 18, 2019.